Charles Ma has become chief scientist of Phalanx Biotech Group, and George Jokhadze director of operations of PhalanxBio, the group’s US subsidiary, the Taiwan-based microarray company said earlier this month. Jokhadze was previously a senior research scientist and group leader at BD Clontech, where he co-developed microarrays. He holds a PhD in molecular biology from the Academy of Sciences in Russia. Ma has been an associate research scientist at Columbia University since 1995. He holds a PhD in molecular biology from the University of California, Los Angeles.
Thomas Higgins has become CFO and executive vice president of Caliper Life Sciences, the company said last week. His appointment will become effective in early January. Higgins currently is executive vice president of operations and CFO of VI Technologies. He holds a BBA from Boston University.
Christohper Yoo will become director of marketing of the molecular biology division of Applied Biosystems starting in January. He joins ABI from IBM’s Information Based Medicine unit, where he was head of strategy. Yoo holds a PhD in molecular and cell biology from Yale University School of Medicine and a BA from the University of Pennsylvania.
Kenneth Bate will leave Millennium Pharmaceuticals, where he is head of commercial operations and an executive vice president, in January, the company said on Monday. His responsibilities will be taken over by CEO Mark Levin. Millennium is currently looking for a successor. In addition, three board members, Ginger Graham, CEO of Amylin Pharmaceuticals; Vaughn Kailian, managing partner of Deerhaven Partners; and Edward Miller, CEO and dean of Johns Hopkins University School of Medicine; will step down in January.
Amit Kumar, CEO and president of CombiMatrix, has been appointed to the board of the NanoBusiness Alliance, an industry association, CombiMatrix’s parent company Acacia Research said on Monday.
William Haseltine has joined the board of directors of the Institute for OneWorld Health, the non-profit company said last week. He was the CEO and chairman of Human Genome Sciences until this fall. Haseltine holds a PhD in biophysics from Harvard University and an undergraduate degree in physical chemistry from the University of California at Berkeley.